Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-03-29-Speech-4-109"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20070329.23.4-109"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
Now that the European directive on medical products has been revised, I wish to say that I am in favour of the European Parliament’s advocacy of a logical separation of regulation and of ‘reprocessing’ being regulated in a separate directive. As representatives of the people, we must do more to make regulations rational and comprehensible, resisting the temptation to force different regulations under a single heading. What the Commission must do now – and as soon as possible rather than in three years’ time – is to put forward a proposal for a separate directive.
Our rapporteur Mr Ulmer, whom I also want to thank for his outstanding work, has made it possible for a sound and even-handed compromise to be reached on the hazardous chemicals in medical products. I am sure that everyone will agree with me that medicines should not contain harmful substances, or, if they do, should contain as few as possible, and so we must aim to effectively phase out all substances that are carcinogenic, mutagenic, or toxic to reproduction.
It is with specific reference to those that I should like once more to highlight the indispensability of proper product labelling. I do not think that the Commission has made the right choice in opting for labelling using the ‘Global Medical Device Nomenclature’. The code makes it inevitable that costs will arise and be incurred primarily by European manufacturers and the general public, to the detriment of competition and to no great benefit to patients."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples